|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KANSL3 |
Gene summary for KANSL3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KANSL3 | Gene ID | 55683 |
| Gene name | KAT8 regulatory NSL complex subunit 3 | |
| Gene Alias | KIAA1310 | |
| Cytomap | 2q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9P2N6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55683 | KANSL3 | LZE4T | Human | Esophagus | ESCC | 1.37e-05 | 1.64e-01 | 0.0811 |
| 55683 | KANSL3 | LZE7T | Human | Esophagus | ESCC | 1.38e-04 | 2.15e-01 | 0.0667 |
| 55683 | KANSL3 | LZE8T | Human | Esophagus | ESCC | 1.65e-02 | 6.44e-02 | 0.067 |
| 55683 | KANSL3 | LZE22T | Human | Esophagus | ESCC | 4.25e-04 | 2.12e-01 | 0.068 |
| 55683 | KANSL3 | LZE24T | Human | Esophagus | ESCC | 1.87e-07 | 1.37e-01 | 0.0596 |
| 55683 | KANSL3 | P1T-E | Human | Esophagus | ESCC | 1.89e-07 | 2.45e-01 | 0.0875 |
| 55683 | KANSL3 | P2T-E | Human | Esophagus | ESCC | 1.64e-21 | 2.27e-01 | 0.1177 |
| 55683 | KANSL3 | P4T-E | Human | Esophagus | ESCC | 3.24e-10 | 2.23e-01 | 0.1323 |
| 55683 | KANSL3 | P5T-E | Human | Esophagus | ESCC | 4.30e-12 | 1.00e-01 | 0.1327 |
| 55683 | KANSL3 | P8T-E | Human | Esophagus | ESCC | 2.73e-14 | 1.88e-01 | 0.0889 |
| 55683 | KANSL3 | P9T-E | Human | Esophagus | ESCC | 1.07e-07 | 1.46e-01 | 0.1131 |
| 55683 | KANSL3 | P10T-E | Human | Esophagus | ESCC | 1.30e-13 | 2.69e-01 | 0.116 |
| 55683 | KANSL3 | P11T-E | Human | Esophagus | ESCC | 4.12e-08 | 3.07e-01 | 0.1426 |
| 55683 | KANSL3 | P12T-E | Human | Esophagus | ESCC | 4.88e-12 | 2.69e-01 | 0.1122 |
| 55683 | KANSL3 | P15T-E | Human | Esophagus | ESCC | 1.01e-08 | 1.84e-01 | 0.1149 |
| 55683 | KANSL3 | P16T-E | Human | Esophagus | ESCC | 3.71e-10 | 8.88e-02 | 0.1153 |
| 55683 | KANSL3 | P20T-E | Human | Esophagus | ESCC | 5.62e-06 | 9.05e-02 | 0.1124 |
| 55683 | KANSL3 | P21T-E | Human | Esophagus | ESCC | 2.07e-10 | 8.02e-02 | 0.1617 |
| 55683 | KANSL3 | P22T-E | Human | Esophagus | ESCC | 1.44e-10 | 1.81e-01 | 0.1236 |
| 55683 | KANSL3 | P23T-E | Human | Esophagus | ESCC | 3.68e-15 | 2.42e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
| GO:00439811 | Esophagus | ESCC | histone H4-K5 acetylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:00439821 | Esophagus | ESCC | histone H4-K8 acetylation | 13/8552 | 15/18723 | 1.31e-03 | 6.26e-03 | 13 |
| GO:004398411 | Esophagus | ESCC | histone H4-K16 acetylation | 16/8552 | 20/18723 | 1.85e-03 | 8.40e-03 | 16 |
| GO:00165703 | Liver | NAFLD | histone modification | 90/1882 | 463/18723 | 5.74e-10 | 1.28e-07 | 90 |
| GO:0018205 | Liver | NAFLD | peptidyl-lysine modification | 65/1882 | 376/18723 | 9.42e-06 | 3.02e-04 | 65 |
| GO:0043543 | Liver | NAFLD | protein acylation | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
| GO:0006473 | Liver | NAFLD | protein acetylation | 37/1882 | 201/18723 | 2.10e-04 | 3.61e-03 | 37 |
| GO:0018394 | Liver | NAFLD | peptidyl-lysine acetylation | 32/1882 | 169/18723 | 3.24e-04 | 5.00e-03 | 32 |
| GO:0018393 | Liver | NAFLD | internal peptidyl-lysine acetylation | 28/1882 | 158/18723 | 2.10e-03 | 2.06e-02 | 28 |
| GO:0006475 | Liver | NAFLD | internal protein amino acid acetylation | 28/1882 | 160/18723 | 2.54e-03 | 2.36e-02 | 28 |
| GO:0016573 | Liver | NAFLD | histone acetylation | 26/1882 | 152/18723 | 4.85e-03 | 3.84e-02 | 26 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KANSL3 | SNV | Missense_Mutation | c.739N>G | p.Leu247Val | p.L247V | Q9P2N6 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| KANSL3 | SNV | Missense_Mutation | rs370690563 | c.868N>T | p.Arg290Cys | p.R290C | Q9P2N6 | protein_coding | deleterious(0.02) | possibly_damaging(0.796) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| KANSL3 | SNV | Missense_Mutation | c.2176N>G | p.Gln726Glu | p.Q726E | Q9P2N6 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.473) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD | |
| KANSL3 | insertion | Nonsense_Mutation | novel | c.2204_2205insGACTGGCTGATTGAAGGGGCTGC | p.Ile735MetfsTer4 | p.I735Mfs*4 | Q9P2N6 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| KANSL3 | insertion | Nonsense_Mutation | novel | c.233_234insGATCACTGCCCTGTAATTATTTTGTATCATCTTCATTGA | p.Ile78delinsMetIleThrAlaLeuTerLeuPheCysIleIlePheIleGlu | p.I78delinsMITAL*LFCIIFIE | Q9P2N6 | protein_coding | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| KANSL3 | deletion | In_Frame_Del | novel | c.827_841delNNNNNNNNNNNNNNN | p.Ile276_Pro281delinsThr | p.I276_P281delinsT | Q9P2N6 | protein_coding | TCGA-BH-A0BA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | ||
| KANSL3 | SNV | Missense_Mutation | novel | c.1039N>A | p.Pro347Thr | p.P347T | Q9P2N6 | protein_coding | deleterious(0.01) | possibly_damaging(0.791) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KANSL3 | SNV | Missense_Mutation | novel | c.1887C>A | p.Asp629Glu | p.D629E | Q9P2N6 | protein_coding | tolerated_low_confidence(0.69) | benign(0.003) | TCGA-Q1-A6DV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KANSL3 | SNV | Missense_Mutation | novel | c.430C>A | p.Leu144Ile | p.L144I | Q9P2N6 | protein_coding | tolerated(0.11) | possibly_damaging(0.542) | TCGA-ZJ-AAXN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KANSL3 | SNV | Missense_Mutation | novel | c.2009N>T | p.Thr670Ile | p.T670I | Q9P2N6 | protein_coding | deleterious_low_confidence(0) | benign(0.047) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |